Pediatric exposures to caffeine energy products increased from 2011 to 2023, although most exposures had minimal clinical effects.

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

The FDA has accepted for Priority Review the NDA for vatiquinone for the treatment of children and adults living with Friedreich ataxia.

A recent study finds that childhood and adult traumatic experiences are independently associated with endometriosis.

Pediatric patients who adopted and sustained a CD exclusion diet achieved clinical remission and reported improvement in clinical symptoms and fecal calprotectin.

Adherence to a healthier, anti-inflammatory diet was associated with a reduced risk for all-cause mortality among patients with RA.

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

Certain metabolic factors are associated with the development of chronic musculoskeletal pain, including higher BMI and the presence of diabetes.

Contemporary estrogen-progestin contraceptives are associated with an increased risk for ischemic stroke and myocardial infarction.

The US FDA has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy.

A recent study finds that women with epilepsy may have offspring with decreased bone metabolism and lower birth weight.